JP2011524420A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2011524420A5 JP2011524420A5 JP2011514735A JP2011514735A JP2011524420A5 JP 2011524420 A5 JP2011524420 A5 JP 2011524420A5 JP 2011514735 A JP2011514735 A JP 2011514735A JP 2011514735 A JP2011514735 A JP 2011514735A JP 2011524420 A5 JP2011524420 A5 JP 2011524420A5
- Authority
- JP
- Japan
- Prior art keywords
- amino acid
- analog
- seq
- optionally
- substitution
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001413 amino acids Chemical class 0.000 claims 46
- 125000003275 alpha amino acid group Chemical group 0.000 claims 33
- 230000004048 modification Effects 0.000 claims 18
- 238000012986 modification Methods 0.000 claims 18
- 238000006467 substitution reaction Methods 0.000 claims 15
- 102100039994 Gastric inhibitory polypeptide Human genes 0.000 claims 12
- 125000002252 acyl group Chemical group 0.000 claims 11
- 230000000694 effects Effects 0.000 claims 11
- 125000006850 spacer group Chemical group 0.000 claims 11
- 108010036598 gastric inhibitory polypeptide receptor Proteins 0.000 claims 10
- 239000000556 agonist Substances 0.000 claims 9
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 claims 9
- 108090000765 processed proteins & peptides Proteins 0.000 claims 9
- 125000000217 alkyl group Chemical group 0.000 claims 8
- MASNOZXLGMXCHN-ZLPAWPGGSA-N glucagon Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 claims 8
- -1 aromatic amino acid Chemical class 0.000 claims 7
- 239000008194 pharmaceutical composition Substances 0.000 claims 6
- 102000051325 Glucagon Human genes 0.000 claims 5
- 108060003199 Glucagon Proteins 0.000 claims 5
- 102000007446 Glucagon-Like Peptide-1 Receptor Human genes 0.000 claims 5
- 108010086246 Glucagon-Like Peptide-1 Receptor Proteins 0.000 claims 5
- 229960004666 glucagon Drugs 0.000 claims 5
- 230000004913 activation Effects 0.000 claims 4
- 210000004899 c-terminal region Anatomy 0.000 claims 4
- 108010016626 Dipeptides Proteins 0.000 claims 3
- 239000002202 Polyethylene glycol Substances 0.000 claims 3
- 229920001223 polyethylene glycol Polymers 0.000 claims 3
- OGNSCSPNOLGXSM-UHFFFAOYSA-N 2,4-diaminobutyric acid Chemical compound NCCC(N)C(O)=O OGNSCSPNOLGXSM-UHFFFAOYSA-N 0.000 claims 2
- 125000001433 C-terminal amino-acid group Chemical group 0.000 claims 2
- 101710198884 GATA-type zinc finger protein 1 Proteins 0.000 claims 2
- DTHNMHAUYICORS-KTKZVXAJSA-N Glucagon-like peptide 1 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 DTHNMHAUYICORS-KTKZVXAJSA-N 0.000 claims 2
- 102100040918 Pro-glucagon Human genes 0.000 claims 2
- 235000014113 dietary fatty acids Nutrition 0.000 claims 2
- 239000000539 dimer Substances 0.000 claims 2
- 229930195729 fatty acid Natural products 0.000 claims 2
- 239000000194 fatty acid Substances 0.000 claims 2
- 150000004665 fatty acids Chemical class 0.000 claims 2
- 125000001924 fatty-acyl group Chemical group 0.000 claims 2
- 230000004927 fusion Effects 0.000 claims 2
- 125000002883 imidazolyl group Chemical group 0.000 claims 2
- 230000001939 inductive effect Effects 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 1
- MTCFGRXMJLQNBG-UWTATZPHSA-N D-Serine Chemical compound OC[C@@H](N)C(O)=O MTCFGRXMJLQNBG-UWTATZPHSA-N 0.000 claims 1
- QNAYBMKLOCPYGJ-UWTATZPHSA-N D-alanine Chemical compound C[C@@H](N)C(O)=O QNAYBMKLOCPYGJ-UWTATZPHSA-N 0.000 claims 1
- 108010067722 Dipeptidyl Peptidase 4 Proteins 0.000 claims 1
- 102100025012 Dipeptidyl peptidase 4 Human genes 0.000 claims 1
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims 1
- DEFJQIDDEAULHB-IMJSIDKUSA-N L-alanyl-L-alanine Chemical compound C[C@H](N)C(=O)N[C@@H](C)C(O)=O DEFJQIDDEAULHB-IMJSIDKUSA-N 0.000 claims 1
- FFFHZYDWPBMWHY-VKHMYHEASA-N L-homocysteine Chemical group OC(=O)[C@@H](N)CCS FFFHZYDWPBMWHY-VKHMYHEASA-N 0.000 claims 1
- LCPYQJIKPJDLLB-UWVGGRQHSA-N Leu-Leu Chemical compound CC(C)C[C@H](N)C(=O)N[C@H](C(O)=O)CC(C)C LCPYQJIKPJDLLB-UWVGGRQHSA-N 0.000 claims 1
- CBQJSKKFNMDLON-JTQLQIEISA-N N-acetyl-L-phenylalanine Chemical group CC(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 CBQJSKKFNMDLON-JTQLQIEISA-N 0.000 claims 1
- 208000008589 Obesity Diseases 0.000 claims 1
- 206010033799 Paralysis Diseases 0.000 claims 1
- RWCOTTLHDJWHRS-YUMQZZPRSA-N Pro-Pro Chemical compound OC(=O)[C@@H]1CCCN1C(=O)[C@H]1NCCC1 RWCOTTLHDJWHRS-YUMQZZPRSA-N 0.000 claims 1
- 108010056243 alanylalanine Proteins 0.000 claims 1
- QWCKQJZIFLGMSD-UHFFFAOYSA-N alpha-aminobutyric acid Chemical compound CCC(N)C(O)=O QWCKQJZIFLGMSD-UHFFFAOYSA-N 0.000 claims 1
- 150000001408 amides Chemical class 0.000 claims 1
- 125000003277 amino group Chemical group 0.000 claims 1
- 125000003118 aryl group Chemical group 0.000 claims 1
- 150000001732 carboxylic acid derivatives Chemical group 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 210000001035 gastrointestinal tract Anatomy 0.000 claims 1
- 125000001072 heteroaryl group Chemical group 0.000 claims 1
- 108010091798 leucylleucine Proteins 0.000 claims 1
- 230000007935 neutral effect Effects 0.000 claims 1
- 235000020824 obesity Nutrition 0.000 claims 1
- 108010077112 prolyl-proline Proteins 0.000 claims 1
- 230000004584 weight gain Effects 0.000 claims 1
- 235000019786 weight gain Nutrition 0.000 claims 1
- 230000004580 weight loss Effects 0.000 claims 1
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US7327408P | 2008-06-17 | 2008-06-17 | |
| US61/073,274 | 2008-06-17 | ||
| US7817108P | 2008-07-03 | 2008-07-03 | |
| US61/078,171 | 2008-07-03 | ||
| US9044808P | 2008-08-20 | 2008-08-20 | |
| US61/090,448 | 2008-08-20 | ||
| US15134909P | 2009-02-10 | 2009-02-10 | |
| US61/151,349 | 2009-02-10 | ||
| PCT/US2009/047447 WO2010011439A2 (en) | 2008-06-17 | 2009-06-16 | Gip-based mixed agonists for treatment of metabolic disorders and obesity |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015076371A Division JP6174071B2 (ja) | 2008-06-17 | 2015-04-02 | 代謝疾患および肥満の治療のためのｇｉｐに基づいた混合アゴニスト |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2011524420A JP2011524420A (ja) | 2011-09-01 |
| JP2011524420A5 true JP2011524420A5 (https=) | 2012-10-25 |
| JP6108659B2 JP6108659B2 (ja) | 2017-04-05 |
Family
ID=41570802
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011514735A Active JP6108659B2 (ja) | 2008-06-17 | 2009-06-16 | 代謝疾患および肥満の治療のためのｇｉｐに基づいた混合アゴニスト |
| JP2015076371A Active JP6174071B2 (ja) | 2008-06-17 | 2015-04-02 | 代謝疾患および肥満の治療のためのｇｉｐに基づいた混合アゴニスト |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015076371A Active JP6174071B2 (ja) | 2008-06-17 | 2015-04-02 | 代謝疾患および肥満の治療のためのｇｉｐに基づいた混合アゴニスト |
Country Status (27)
| Country | Link |
|---|---|
| US (2) | US9062124B2 (https=) |
| EP (2) | EP2952202B1 (https=) |
| JP (2) | JP6108659B2 (https=) |
| KR (1) | KR20110040760A (https=) |
| CN (2) | CN104945500B (https=) |
| AR (1) | AR072159A1 (https=) |
| AU (1) | AU2009274425B2 (https=) |
| BR (1) | BRPI0915282A2 (https=) |
| CA (1) | CA2729296A1 (https=) |
| CL (1) | CL2009001425A1 (https=) |
| CO (1) | CO6280539A2 (https=) |
| CR (1) | CR11849A (https=) |
| DK (1) | DK2300035T3 (https=) |
| EA (1) | EA020326B9 (https=) |
| EC (1) | ECSP10010684A (https=) |
| ES (2) | ES2650038T3 (https=) |
| HU (1) | HUE028072T2 (https=) |
| IL (1) | IL209666A (https=) |
| MA (1) | MA32397B1 (https=) |
| MX (1) | MX2010013453A (https=) |
| NZ (2) | NZ603445A (https=) |
| PE (1) | PE20100056A1 (https=) |
| PL (1) | PL2300035T3 (https=) |
| SG (1) | SG192405A1 (https=) |
| TW (1) | TWI474835B (https=) |
| WO (1) | WO2010011439A2 (https=) |
| ZA (1) | ZA201008807B (https=) |
Families Citing this family (144)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2570133B1 (en) | 2005-11-07 | 2016-03-23 | Indiana University Research and Technology Corporation | Glucagon analogs exhibiting physiological solubility and stability |
| RU2477286C2 (ru) * | 2007-01-05 | 2013-03-10 | Индиана Юниверсити Рисерч Энд Текнолоджи Корпорейшн | АНАЛОГИ ГЛЮКАГОНА, ОБЛАДАЮЩИЕ ПОВЫШЕННОЙ РАСТВОРИМОСТЬЮ В БУФЕРАХ С ФИЗИОЛОГИЧЕСКИМ ЗНАЧЕНИЕМ pH |
| AU2008216265B2 (en) * | 2007-02-15 | 2014-04-03 | Indiana University Research And Technology Corporation | Glucagon/GLP-1 receptor co-agonists |
| WO2009058662A2 (en) | 2007-10-30 | 2009-05-07 | Indiana University Research And Technology Corporation | Glucagon antagonists |
| US8980830B2 (en) * | 2007-10-30 | 2015-03-17 | Indiana University Research And Technology Corporation | Peptide compounds exhibiting glucagon antagonist and GLP-1 agonist activity |
| AU2009210570B2 (en) * | 2008-01-30 | 2014-11-20 | Indiana University Research And Technology Corporation | Ester-based insulin prodrugs |
| NZ588603A (en) | 2008-03-26 | 2012-03-30 | Oramed Ltd | Methods and compositions for oral administration of a protein of up to 100000 Daltaons, a first protease inhibitor and a second protease inhibitor wherein said protease inhibitors inhibit trypsin |
| CN105903005A (zh) | 2008-05-05 | 2016-08-31 | 奥拉姆德有限公司 | 用于口服给予艾塞那肽的方法和组合物 |
| WO2009155257A1 (en) | 2008-06-17 | 2009-12-23 | Indiana University Research And Technology Corporation | Glucagon analogs exhibiting enhanced solubility and stability physiological ph buffers |
| EP2300037B1 (en) | 2008-06-17 | 2016-03-30 | Indiana University Research and Technology Corporation | Glucagon/glp-1 receptor co-agonists |
| DK2300035T3 (en) | 2008-06-17 | 2015-11-16 | Univ Indiana Res & Tech Corp | Mixed GIP-based agonists for the treatment of metabolic diseases and obesity |
| CN102325539A (zh) | 2008-12-19 | 2012-01-18 | 印第安纳大学研究及科技有限公司 | 基于酰胺的胰高血糖素超家族肽前药 |
| WO2010118034A2 (en) * | 2009-04-06 | 2010-10-14 | Board Of Regents, The University Of Texas System | Cyclic peptide analogues for non-invasive imaging of pancreatic beta-cells |
| WO2010148089A1 (en) * | 2009-06-16 | 2010-12-23 | Indiana University Research And Technology Corporation | Gip receptor-active glucagon compounds |
| AP3329A (en) | 2009-07-13 | 2015-06-30 | Zealand Pharma As | Acylated glucagon analogues |
| US8703701B2 (en) | 2009-12-18 | 2014-04-22 | Indiana University Research And Technology Corporation | Glucagon/GLP-1 receptor co-agonists |
| EP2528618A4 (en) * | 2010-01-27 | 2015-05-27 | Univ Indiana Res & Tech Corp | GLUCAGON ANTAGONISTE AND GIP AGONISTS CONJUGATES AND COMPOSITIONS FOR THE TREATMENT OF METABOLISM DISEASES AND ADIPOSITAS |
| AR080592A1 (es) * | 2010-03-26 | 2012-04-18 | Lilly Co Eli | Peptido con actividad para el gip-r y glp-1-r, formulacion famaceutica que lo comprende, su uso para preparar un medicamento util para el tratamiento de diabetes mellitus y para inducir la perdida de peso |
| WO2011143208A1 (en) | 2010-05-13 | 2011-11-17 | Indiana University Research And Technology Corporation | Glucagon superfamily peptides exhibiting g protein-coupled receptor activity |
| CA2797095A1 (en) | 2010-05-13 | 2011-11-17 | Indiana University Research And Technology Corporation | Glucagon superfamily peptides exhibiting nuclear hormone receptor activity |
| RU2580317C2 (ru) | 2010-06-24 | 2016-04-10 | Индиана Юниверсити Рисерч Энд Текнолоджи Корпорейшн | Пептидные пролекарства, принадлежащие к суперсемейству амид-содержащих глюкагонов |
| US9023986B2 (en) | 2010-10-25 | 2015-05-05 | Hoffmann-La Roche Inc. | Glucose-dependent insulinotropic peptide analogs |
| EP2635296B1 (en) | 2010-11-03 | 2014-12-24 | Arecor Limited | Novel composition comprising glucagon |
| SG191252A1 (en) | 2010-12-22 | 2013-07-31 | Marcadia Biotech Inc | Methods for treating metabolic disorders and obesity with gip and glp-1 receptor-active glucagon-based peptides |
| US8507428B2 (en) * | 2010-12-22 | 2013-08-13 | Indiana University Research And Technology Corporation | Glucagon analogs exhibiting GIP receptor activity |
| JP2014510739A (ja) | 2011-03-28 | 2014-05-01 | ノヴォ ノルディスク アー／エス | 新規のグルカゴン類似体 |
| EP2694095B1 (en) | 2011-04-05 | 2018-03-07 | Longevity Biotech, Inc. | Compositions comprising glucagon analogs and methods of making and using the same |
| WO2012167744A1 (en) * | 2011-06-10 | 2012-12-13 | Beijing Hanmi Pharmaceutical Co., Ltd. | Glucose dependent insulinotropic polypeptide analogs, pharmaceutical compositions and use thereof |
| RS56173B1 (sr) | 2011-06-22 | 2017-11-30 | Univ Indiana Res & Tech Corp | Koagonisti receptora za glukagon/glp-1 receptora |
| BR112013032717A2 (pt) | 2011-06-22 | 2017-01-24 | Univ Indiana Res & Tech Corp | coagonistas do receptor de glucagon/glp-1 |
| WO2013004983A1 (en) | 2011-07-04 | 2013-01-10 | Imperial Innovations Limited | Novel compounds and their effects on feeding behaviour |
| RU2610175C2 (ru) | 2011-09-23 | 2017-02-08 | Ново Нордиск А/С | Новые аналоги глюкагона |
| RU2014117678A (ru) | 2011-11-17 | 2015-12-27 | Индиана Юниверсити Рисерч Энд Текнолоджи Корпорейшн | Пептиды глюкагонового суперсемейства, обладающие глюкокортикоидной рецепторной активностью |
| JP6567827B2 (ja) | 2012-02-01 | 2019-08-28 | オラムド エルティーディー． | プロテアーゼ阻害剤を含有する組成物、該組成物を含む組成物、および、該組成物を製造および使用する方法 |
| JP6228187B2 (ja) * | 2012-05-03 | 2017-11-08 | ジーランド ファーマ アクティーゼルスカブ | Ｇｉｐ−ｇｌｐ−１デュアルアゴニスト化合物及び方法 |
| WO2013170636A1 (zh) | 2012-05-18 | 2013-11-21 | 爱德迪安（北京）生物技术有限公司 | 用于糖尿病治疗的蛋白、蛋白缀合物及其应用 |
| TW201402611A (zh) | 2012-06-21 | 2014-01-16 | Univ Indiana Res & Tech Corp | 具有改變之ｆｃ效應子功能之腸促胰島素受體配體多肽ｆｃ區融合多肽及結合物 |
| HRP20180936T1 (hr) | 2012-06-21 | 2018-12-14 | Indiana University Research And Technology Corporation | Analozi glukagona koji pokazuju aktivnost prema receptoru za gip |
| CA2877358A1 (en) | 2012-06-21 | 2013-12-27 | Indiana University Research And Technology Corporation | Glucagon analogs exhibiting gip receptor activity |
| AU2013295035B2 (en) | 2012-07-23 | 2017-08-03 | Zealand Pharma A/S | Glucagon analogues |
| TWI608013B (zh) | 2012-09-17 | 2017-12-11 | 西蘭製藥公司 | 升糖素類似物 |
| AR092873A1 (es) | 2012-09-26 | 2015-05-06 | Cadila Healthcare Ltd | Peptidos como agonistas triples de los receptores de gip, glp-1 y glugagon |
| UA116217C2 (uk) | 2012-10-09 | 2018-02-26 | Санофі | Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону |
| HK1211232A1 (en) | 2012-12-21 | 2016-05-20 | Sanofi | Exendin-4 derivatives as dual glp1/gip or trigonal glp1/gip/glucagon agonists |
| CN104902921A (zh) * | 2013-01-03 | 2015-09-09 | 奥拉姆德有限公司 | 用于治疗nafld、肝性脂肪变性及其后遗症的方法和组合物 |
| WO2014158900A1 (en) | 2013-03-14 | 2014-10-02 | Indiana University Research And Technology Corporation | Insulin-incretin conjugates |
| CN105324125A (zh) * | 2013-03-15 | 2016-02-10 | 印第安纳大学研究及科技有限公司 | 具有长效的前体药物 |
| WO2014147129A1 (en) | 2013-03-21 | 2014-09-25 | Sanofi-Aventis Deutschland Gmbh | Synthesis of cyclic imide containing peptide products |
| CN105189465B (zh) | 2013-03-21 | 2019-02-26 | 赛诺菲-安万特德国有限公司 | 合成含有乙内酰脲的肽产物 |
| WO2014161835A1 (en) | 2013-04-03 | 2014-10-09 | Sanofi | Modified blood glucose regulating proteins with altered pharmacological activity profile and preparation thereof |
| SI2986313T1 (sl) | 2013-04-18 | 2019-09-30 | Novo Nordisk A/S | Stabilni koagonisti GLP-1 / glukagonskega receptorja z dolgotrajnim učinkom za medicinsko uporabo |
| LT3004155T (lt) * | 2013-05-28 | 2021-12-27 | Takeda Pharmaceutical Company Limited | Peptidų junginys |
| HK1226084A1 (zh) * | 2013-08-16 | 2017-09-22 | Medimmune Limited | 用於治疗糖尿病的gip和glp-1受体双重激动剂 |
| WO2015035419A1 (en) * | 2013-09-09 | 2015-03-12 | Hoffmann-La Roche Inc. | Dosages of gip/glp-1 co-agonist peptides for human administration |
| US9988429B2 (en) | 2013-10-17 | 2018-06-05 | Zealand Pharma A/S | Glucagon analogues |
| WO2015055801A1 (en) | 2013-10-17 | 2015-04-23 | Zealand Pharma A/S | Acylated glucagon analogues |
| AU2014345570B2 (en) | 2013-11-06 | 2019-01-24 | Zealand Pharma A/S | Glucagon-GLP-1-GIP triple agonist compounds |
| MX2016005556A (es) * | 2013-11-06 | 2016-07-15 | Zealand Pharma As | Compuestos agonistas duales de gip-glp-1 y procedimientos. |
| CN112043835B (zh) | 2013-12-06 | 2022-10-21 | 韩捷 | 用于含氮和羟基的药物的生物可逆引入基团 |
| WO2015086732A1 (en) * | 2013-12-13 | 2015-06-18 | Sanofi | Exendin-4 peptide analogues |
| EP3080152A1 (en) | 2013-12-13 | 2016-10-19 | Sanofi | Non-acylated exendin-4 peptide analogues |
| WO2015086733A1 (en) | 2013-12-13 | 2015-06-18 | Sanofi | Dual glp-1/glucagon receptor agonists |
| EP3080155A1 (en) * | 2013-12-13 | 2016-10-19 | Sanofi | Exendin-4 peptide analogues as dual glp-1/glucagon receptor agonists |
| WO2015086728A1 (en) * | 2013-12-13 | 2015-06-18 | Sanofi | Exendin-4 peptide analogues as dual glp-1/gip receptor agonists |
| TW201609799A (zh) * | 2013-12-13 | 2016-03-16 | 賽諾菲公司 | 雙重ｇｌｐ－１／ｇｉｐ受體促效劑 |
| AR098614A1 (es) | 2013-12-18 | 2016-06-01 | Lilly Co Eli | Compuesto para el tratamiento de hipoglicemia severa |
| AU2014364589B2 (en) | 2013-12-18 | 2020-02-27 | The California Institute For Biomedical Research | Modified therapeutic agents, stapled peptide lipid conjugates, and compositions thereof |
| WO2015095684A1 (en) | 2013-12-20 | 2015-06-25 | Indiana University Research And Technology Corporation | Lipidated incretin receptor ligand human immunoglobulin fc-region fusion polypeptides |
| WO2015124612A1 (en) | 2014-02-18 | 2015-08-27 | Novo Nordisk A/S | Stable glucagon analogues and use for treatment of hypoglycaemia |
| TW201625668A (zh) | 2014-04-07 | 2016-07-16 | 賽諾菲公司 | 作為胜肽性雙重ｇｌｐ－１／昇糖素受體激動劑之艾塞那肽－４衍生物 |
| TW201625670A (zh) | 2014-04-07 | 2016-07-16 | 賽諾菲公司 | 衍生自ｅｘｅｎｄｉｎ－４之雙重ｇｌｐ－１／升糖素受體促效劑 |
| TW201625669A (zh) | 2014-04-07 | 2016-07-16 | 賽諾菲公司 | 衍生自艾塞那肽－４（Ｅｘｅｎｄｉｎ－４）之肽類雙重ＧＬＰ－１／升糖素受體促效劑 |
| US10570184B2 (en) | 2014-06-04 | 2020-02-25 | Novo Nordisk A/S | GLP-1/glucagon receptor co-agonists for medical use |
| US9932381B2 (en) | 2014-06-18 | 2018-04-03 | Sanofi | Exendin-4 derivatives as selective glucagon receptor agonists |
| ES2822994T3 (es) | 2014-09-24 | 2021-05-05 | Univ Indiana Res & Tech Corp | Conjugados de incretina-insulina |
| CR20170164A (es) | 2014-10-24 | 2017-08-29 | Merck Sharp & Dohme | Coagonistas de los receptores de glucagón y de glp-1 |
| US10253078B2 (en) | 2014-10-29 | 2019-04-09 | Zealand Pharma A/S | GIP agonist compounds and methods |
| WO2016077220A1 (en) * | 2014-11-10 | 2016-05-19 | Mb2 Llc | Gip/glp-1 co-agonist peptides for human administration |
| JP2018012644A (ja) * | 2014-11-26 | 2018-01-25 | 武田薬品工業株式会社 | ペプチド化合物 |
| MY185334A (en) | 2014-12-30 | 2021-05-06 | Hanmi Pharm Ind Co Ltd | Glucagon derivatives with improved stability |
| US10336802B2 (en) | 2015-04-16 | 2019-07-02 | Zealand Pharma A/S | Acylated glucagon analogue |
| AR105319A1 (es) | 2015-06-05 | 2017-09-27 | Sanofi Sa | Profármacos que comprenden un conjugado agonista dual de glp-1 / glucagón conector ácido hialurónico |
| WO2016198624A1 (en) | 2015-06-12 | 2016-12-15 | Sanofi | Exendin-4 derivatives as trigonal glp-1/glucagon/gip receptor agonists |
| EA201890058A1 (ru) | 2015-06-30 | 2018-07-31 | Ханми Фарм. Ко., Лтд. | Производное глюкагона и композиция, содержащая длительно действующий конъюгат этого производного |
| AR105284A1 (es) | 2015-07-10 | 2017-09-20 | Sanofi Sa | Derivados de exendina-4 como agonistas peptídicos duales específicos de los receptores de glp-1 / glucagón |
| TWI622596B (zh) | 2015-10-26 | 2018-05-01 | 美國禮來大藥廠 | 升糖素受體促效劑 |
| WO2017116204A1 (ko) | 2015-12-31 | 2017-07-06 | 한미약품 주식회사 | 글루카곤, glp-1 및 gip 수용체 모두에 활성을 갖는 삼중 활성체 |
| WO2017204219A1 (ja) | 2016-05-24 | 2017-11-30 | 武田薬品工業株式会社 | ペプチド化合物 |
| GB201611077D0 (en) | 2016-06-24 | 2016-08-10 | Arecor Ltd | Novel composition |
| KR102005457B1 (ko) * | 2016-06-29 | 2019-07-30 | 한미약품 주식회사 | 글루카곤 유도체, 이의 결합체, 및 이를 포함하는 조성물, 및 이의 치료적 용도 |
| CN109200273B (zh) * | 2017-07-04 | 2021-02-19 | 中国药科大学 | 一种多肽用于制备预防或治疗脂肪肝病药物的用途 |
| AR110300A1 (es) | 2016-12-02 | 2019-03-13 | Sanofi Sa | Compuestos como agonistas peptídicos trigonales de los receptores de glp1 / glucagón / gip |
| TW201833131A (zh) | 2016-12-02 | 2018-09-16 | 法商賽諾菲公司 | 作為胜肽類ｇｌｐ１／升糖素／ｇｉｐ受體促效劑之新化合物 |
| GB201620611D0 (en) * | 2016-12-05 | 2017-01-18 | Univ Of Lancaster | Treatment of neurological diseases |
| US11285180B2 (en) | 2016-12-06 | 2022-03-29 | Inserm (Institut National De La Sante Et De La Recherche Medicale) | Methods of enhancing the potency of incretin-based drugs in subjects in need thereof |
| JOP20190211A1 (ar) | 2017-03-31 | 2019-09-15 | Takeda Pharmaceuticals Co | ببتيد منشط لمستقبل gip |
| TWI912614B (zh) * | 2017-12-21 | 2026-01-21 | 美商美國禮來大藥廠 | 腸促胰島素(incretin)類似物及其用途 |
| WO2019183577A1 (en) * | 2018-03-23 | 2019-09-26 | Carmot Therapeutics, Inc. | Modulators of g-protein coupled receptors |
| MX2020010716A (es) | 2018-04-10 | 2021-03-09 | Sanofi Aventis Deutschland | Metodo para escindir de la fase solida peptidos unidos a una fase solida. |
| EP3774838B9 (en) | 2018-04-10 | 2025-12-10 | Sanofi-Aventis Deutschland GmbH | Lixisenatide synthesis with capping |
| KR102379958B1 (ko) | 2018-05-04 | 2022-04-01 | 노보 노르디스크 에이/에스 | Gip 유도체 및 이의 용도 |
| UY38249A (es) | 2018-05-30 | 2019-12-31 | Sanofi Sa | Productos conjugados que comprenden un agonista del receptor triple de glp-1/glucagón/gip, un conector y ácido hialurónico |
| EP3856339A1 (en) | 2018-09-24 | 2021-08-04 | Takeda Pharmaceutical Company Limited | Gip receptor agonist peptide compounds and uses thereof |
| WO2021083306A1 (zh) * | 2019-10-31 | 2021-05-06 | 东莞市东阳光生物药研发有限公司 | Glp-1/gcg双受体激动剂多肽 |
| AU2020397917A1 (en) | 2019-12-04 | 2022-06-23 | The Scripps Research Institute | GLP2 receptor agonists and methods of use |
| CN119841865A (zh) | 2020-02-07 | 2025-04-18 | 加舒布鲁姆生物公司 | 杂环glp-1激动剂 |
| WO2021169512A1 (zh) * | 2020-02-24 | 2021-09-02 | 中山大学 | 多肽化合物及其在预防或治疗糖尿病或糖尿病并发症中的应用 |
| FI4143183T3 (fi) | 2020-04-29 | 2026-01-07 | Gasherbrum Bio Inc | Heterosyklisiä glp-1-agonisteja |
| BR112023000229A2 (pt) | 2020-07-22 | 2023-01-31 | Novo Nordisk As | Composto, composição farmacêutica, e, peptídeo |
| MX2023000303A (es) | 2020-07-22 | 2023-02-09 | Novo Nordisk As | Coagonistas de los receptores del peptido 1 similar al glucagon (glp-1) y del polipeptido insulinotropico dependiente de glucosa (gip) adecuados para el suministro oral. |
| EP4236991A1 (en) * | 2020-10-30 | 2023-09-06 | Novo Nordisk A/S | Glp-1, gip and glucagon receptor triple agonists |
| CN114617956B (zh) * | 2020-12-10 | 2023-10-03 | 江苏中新医药有限公司 | 一种高效降糖的蛋白质药物 |
| IL308392A (en) | 2021-05-13 | 2024-01-01 | Carmot Therapeutics Inc | G protein-coupled receptor modulators |
| MX2023014771A (es) * | 2021-06-09 | 2024-03-19 | Scripps Research Inst | Conjugados peptidicos duales gip/glp-1 de accion prolongada y metodos de uso. |
| US20250223331A1 (en) * | 2021-09-02 | 2025-07-10 | Sunshine Lake Pharma Co., Ltd. | Glp-1/gip dual-targeted polypeptide and fusion protein and applications thereof |
| TW202330584A (zh) | 2022-01-20 | 2023-08-01 | 丹麥商諾佛 儂迪克股份有限公司 | 前藥及其用途 |
| CN119137124A (zh) | 2022-03-09 | 2024-12-13 | 加舒布鲁姆生物公司 | 杂环glp-1激动剂 |
| WO2023179542A1 (en) | 2022-03-21 | 2023-09-28 | Gasherbrum Bio , Inc. | 5,8-dihydro-1,7-naphthyridine derivatives as glp-1 agonists for the treatment of diabetes |
| WO2023198140A1 (en) | 2022-04-14 | 2023-10-19 | Gasherbrum Bio, Inc. | Heterocyclic glp-1 agonists |
| CN115490760B (zh) * | 2022-07-04 | 2023-04-14 | 北京惠之衡生物科技有限公司 | 一种glp-1受体和gcg受体共激动多肽衍生物 |
| JP2026501171A (ja) | 2022-12-15 | 2026-01-14 | ガシャーブラム・バイオ・インコーポレイテッド | Ｇｌｐ－１アゴニスト活性を有する化合物の塩および固体形態 |
| JP2026501285A (ja) | 2022-12-22 | 2026-01-14 | ガシャーブラム・バイオ・インコーポレイテッド | ヘテロ環式ｇｌｐ－１アゴニスト |
| CN120693338A (zh) | 2022-12-22 | 2025-09-23 | 加舒布鲁姆生物公司 | 杂环的glp-1激动剂 |
| CN118255864A (zh) * | 2022-12-26 | 2024-06-28 | 杭州中美华东制药有限公司 | Gip受体激动剂及其用途 |
| WO2024165571A2 (en) | 2023-02-06 | 2024-08-15 | E-Therapeutics Plc | Inhibitors of expression and/or function |
| AU2024222719A1 (en) | 2023-02-16 | 2025-08-21 | Gasherbrum Bio, Inc. | Heterocyclic glp-1 agonists |
| US20250019389A1 (en) | 2023-06-30 | 2025-01-16 | Gasherbrum Bio, Inc. | Heterocyclic agonists |
| WO2025015269A1 (en) | 2023-07-13 | 2025-01-16 | Aconcagua Bio, Inc. | Compounds, compositions, and methods |
| WO2025015268A1 (en) | 2023-07-13 | 2025-01-16 | Aconcagua Bio, Inc. | Modulators of calcitonin receptor and/or amylin receptor activity |
| WO2025016303A1 (zh) * | 2023-07-14 | 2025-01-23 | 北京拓界生物医药科技有限公司 | Glp-1、gip和gcg受体三激动剂及其应用 |
| WO2025045208A1 (en) | 2023-08-31 | 2025-03-06 | Gasherbrum Bio, Inc. | Heteroaryl-heterocycloalkyl-based glp-1 agonists |
| CN117186206B (zh) * | 2023-10-20 | 2024-07-23 | 广东药科大学 | 新型不同glp1类似肽共价聚合体及其制备方法和应用 |
| CN120349392A (zh) * | 2023-11-06 | 2025-07-22 | 成都奥达生物科技有限公司 | 一种gip激动剂化合物 |
| JP7755031B2 (ja) | 2023-11-30 | 2025-10-15 | ノヴォ ノルディスク アー／エス | Ｇｌｐ－１、ｇｉｐ、およびアミリン受容体の三重作動薬 |
| WO2025125576A2 (en) | 2023-12-15 | 2025-06-19 | E-Therapeutics Plc | Inhibitors of expression and/or function |
| WO2025137307A1 (en) | 2023-12-20 | 2025-06-26 | Gasherbrum Bio, Inc. | Heterocyclic glp-1 agonists |
| WO2025133348A1 (en) | 2023-12-22 | 2025-06-26 | E-Therapeutics Plc | Inhibitors of expression and/or function |
| EP4686757A1 (en) | 2024-07-31 | 2026-02-04 | e-therapeutics PLC | Inhibitors of expression and/or function |
| WO2025171341A2 (en) | 2024-02-08 | 2025-08-14 | Aconcagua Bio, Inc. | Compounds and compositions for treating conditions associated with calcitonin receptor and/or amylin receptor activity |
| WO2025171340A1 (en) | 2024-02-08 | 2025-08-14 | Aconcagua Bio, Inc. | The treatment of calcitonin- and/or amylin-receptor associated conditions |
| WO2025189141A1 (en) | 2024-03-08 | 2025-09-12 | Annapurna Bio, Inc. | Methods for treating obesity and increasing weight loss |
| WO2025196502A1 (en) | 2024-03-20 | 2025-09-25 | North Carolina Agricultural & Technical State University | Choline kinase inhibitors as a therapeutic treatment for obesity |
| WO2026041075A1 (en) | 2024-08-21 | 2026-02-26 | Gasherbrum Bio, Inc. | Gpl-1 agonists |
| WO2026051998A1 (en) | 2024-09-04 | 2026-03-12 | Aconcagua Bio, Inc. | Compounds, compositions, and methods |
Family Cites Families (132)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4275152A (en) * | 1977-02-03 | 1981-06-23 | Eastman Kodak Company | Hydrolysis of protein-bound cholesterol esters |
| PT83613B (en) | 1985-10-28 | 1988-11-21 | Lilly Co Eli | Process for the selective chemical removal of a protein amino-terminal residue |
| AU597574B2 (en) | 1986-03-07 | 1990-06-07 | Massachusetts Institute Of Technology | Method for enhancing glycoprotein stability |
| JPH04504416A (ja) * | 1989-02-17 | 1992-08-06 | コセルコ・ミモトープス・ピィ・ティ・ワイ．エル・ティ・ディ． | ペプチドの使用方法と合成方法 |
| US5545618A (en) * | 1990-01-24 | 1996-08-13 | Buckley; Douglas I. | GLP-1 analogs useful for diabetes treatment |
| ATE164852T1 (de) | 1990-01-24 | 1998-04-15 | Douglas I Buckley | Glp-1-analoga verwendbar in der diabetesbehandlung |
| CA2024855C (en) | 1990-09-07 | 1997-12-09 | Boehringer Ingelheim (Canada) Ltd./ Boehringer Ingelheim (Canada) Ltee | Process and intermediates for producing glucagon |
| JPH04145099A (ja) | 1990-10-05 | 1992-05-19 | Sanwa Kagaku Kenkyusho Co Ltd | Ｇｉｐ様活性を有するポリペプチド誘導体及びその用途 |
| US5510459A (en) * | 1991-01-17 | 1996-04-23 | Zymogenetics, Inc. | Glucagon antagonists |
| CA2100874A1 (en) * | 1991-01-17 | 1992-07-18 | Robert A. Smith | Methods for detecting glucagon antagonists |
| US5359030A (en) * | 1993-05-10 | 1994-10-25 | Protein Delivery, Inc. | Conjugation-stabilized polypeptide compositions, therapeutic delivery and diagnostic formulations comprising same, and method of making and using the same |
| US5480867A (en) * | 1993-12-29 | 1996-01-02 | The Rockefeller University | Glucagon analogs with serine replacements |
| US5512549A (en) * | 1994-10-18 | 1996-04-30 | Eli Lilly And Company | Glucagon-like insulinotropic peptide analogs, compositions, and methods of use |
| US5869602A (en) | 1995-03-17 | 1999-02-09 | Novo Nordisk A/S | Peptide derivatives |
| JPH0940699A (ja) * | 1995-07-28 | 1997-02-10 | Sanwa Kagaku Kenkyusho Co Ltd | ポリペプチド及びその用途 |
| DE19530865A1 (de) | 1995-08-22 | 1997-02-27 | Michael Dr Med Nauck | Wirkstoff sowie Mittel zur parenteralen Ernährung |
| WO1997029180A1 (en) | 1996-02-06 | 1997-08-14 | Eli Lilly And Company | Diabetes therapy |
| DE59712555D1 (de) | 1996-06-05 | 2006-04-06 | Roche Diagnostics Gmbh | Exendin-analoga, verfahren zu deren herstellung und diese enthaltende arzneimittel |
| WO1998011126A1 (en) | 1996-09-09 | 1998-03-19 | Zealand Pharmaceuticals A/S | Peptide prodrugs containing an alpha-hydroxyacid linker |
| UA65549C2 (uk) | 1996-11-05 | 2004-04-15 | Елі Ліллі Енд Компані | Спосіб регулювання ожиріння шляхом периферійного введення аналогів та похідних glp-1 (варіанти) та фармацевтична композиція |
| WO1998024464A1 (en) | 1996-12-03 | 1998-06-11 | Trustees Of Boston University | Specific antagonists for glucose-dependent insulinotropic polypeptide (gip) |
| JP4394279B2 (ja) | 1998-03-09 | 2010-01-06 | ジーランド ファーマ アクティーゼルスカブ | 酵素加水分解に対する傾向が減少した薬理学的に活性なペプチド複合体 |
| DE19828113A1 (de) | 1998-06-24 | 2000-01-05 | Probiodrug Ges Fuer Arzneim | Prodrugs von Inhibitoren der Dipeptidyl Peptidase IV |
| US20030236190A1 (en) * | 1998-09-02 | 2003-12-25 | Renuka Pillutla | Isulin and IGF-1 receptor agonists and antagonists |
| JP2002526554A (ja) | 1998-10-07 | 2002-08-20 | メディカル カレッジ オブ ジョージア リサーチ インスティチュート，インコーポレイテッド | 骨親和性ホルモンとして用いられるグルコース依存性インスリン親和性ペプチド |
| DE69922043T2 (de) * | 1998-12-07 | 2005-11-24 | Société de Conseils de Recherches et d'Applications Scientifiques S.A.S. | Glp-1 analoge |
| JP2002534512A (ja) | 1999-01-15 | 2002-10-15 | ノボ ノルディスク アクティーゼルスカブ | 非ペプチドｇｌｐ−１アゴニスト |
| GB0404124D0 (en) | 2004-02-25 | 2004-03-31 | Univ Ulster | Antagonists of GIP |
| PT1171465E (pt) | 1999-03-29 | 2004-12-31 | Uutech Ltd | Analogos de petido inibidor gastrico e sua utilizacao para o tratamento de diabetes |
| CA2363712C (en) | 1999-05-17 | 2011-05-10 | Conjuchem Inc. | Long lasting insulinotropic peptides |
| EP1076066A1 (en) * | 1999-07-12 | 2001-02-14 | Zealand Pharmaceuticals A/S | Peptides for lowering blood glucose levels |
| KR20020097236A (ko) | 2000-04-27 | 2002-12-31 | 바이오네브라스카, 인코포레이티드 | 타입-2 당뇨병, 내당능 장애, 또는 공복 혈당 장애에 대한감수성을 검출하기 위한 위억제성 폴리펩티드 진단 시험 |
| US6677136B2 (en) * | 2000-05-03 | 2004-01-13 | Amgen Inc. | Glucagon antagonists |
| AU2001269833A1 (en) * | 2000-06-14 | 2001-12-24 | Cytovax Biotechnologies, Inc. | Use of coiled-coil structural scaffold to generate structure-specific peptides |
| ATE424413T1 (de) | 2000-06-16 | 2009-03-15 | Lilly Co Eli | Analoge des glucagon-ähnlichen peptids-1 |
| WO2002010195A2 (en) | 2000-08-02 | 2002-02-07 | Theratechnologies Inc. | Modified peptides with increased potency |
| US6846831B2 (en) | 2000-08-15 | 2005-01-25 | Cpd, Llc | Method of treating the syndrome of lipodystrophy |
| US6528520B2 (en) | 2000-08-15 | 2003-03-04 | Cpd, Llc | Method of treating the syndrome of coronary heart disease risk factors in humans |
| US20020045572A1 (en) | 2000-08-15 | 2002-04-18 | Cpd, Llc | Method of treating the syndrome of type 2 diabetes in humans |
| US6262062B1 (en) | 2000-08-15 | 2001-07-17 | Cpd, Llc | Method of treating the syndrome of coronary heart disease risk factors in humans |
| US7052686B2 (en) * | 2000-09-29 | 2006-05-30 | Schering Corporation | Pegylated interleukin-10 |
| EP1351984A2 (en) | 2000-12-13 | 2003-10-15 | Eli Lilly And Company | Amidated glucagon-like peptide-1 |
| EP1411968B1 (en) | 2001-07-31 | 2008-09-17 | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | Glp-1 exendin-4 peptide analogs and uses thereof |
| US20040002468A1 (en) * | 2001-08-08 | 2004-01-01 | Genzyme Corporation | Methods of treating diabetes and other blood sugar disorders |
| CA2452044A1 (en) | 2001-08-28 | 2003-03-13 | Eli Lilly And Company | Pre-mixes of glp-1 and basal insulin |
| GB0121709D0 (en) * | 2001-09-07 | 2001-10-31 | Imp College Innovations Ltd | Food inhibition agent |
| AR036711A1 (es) * | 2001-10-05 | 2004-09-29 | Bayer Corp | Peptidos que actuan como agonistas del receptor del glp-1 y como antagonistas del receptor del glucagon y sus metodos de uso farmacologico |
| US6864069B2 (en) | 2001-10-05 | 2005-03-08 | Bayer Pharmaceuticals Corporation | Peptides acting as both GLP-1 receptor agonists and glucagon receptor antagonists and their pharmacological methods of use |
| US7041646B2 (en) * | 2001-10-05 | 2006-05-09 | Bayer Pharmaceuticals Corporation | Methods of treating type 2 diabetes with peptides acting as both GLP-1 receptor agonists and glucagon receptor antagonists |
| CA2463908A1 (en) * | 2001-10-18 | 2003-04-24 | Bristol-Myers Squibb Company | Human glucagon-like-peptide-1 mimics and their use in the treatment of diabetes and related conditions |
| WO2003035099A1 (en) | 2001-10-19 | 2003-05-01 | Eli Lilly And Company | Biphasic mixtures of glp-1 and insulin |
| JP2005518408A (ja) * | 2001-12-29 | 2005-06-23 | ノボ ノルディスク アクティーゼルスカブ | 異常脂肪血症を治療するための、ｇｌｐ−１化合物と他の薬物との組み合わせ使用 |
| MXPA04006679A (es) | 2002-01-08 | 2004-11-10 | Lilly Co Eli | Analogos extendidos de peptido-1 de tipo glucagon. |
| US20030232761A1 (en) | 2002-03-28 | 2003-12-18 | Hinke Simon A. | Novel analogues of glucose-dependent insulinotropic polypeptide |
| AU2003239478A1 (en) | 2002-06-04 | 2003-12-22 | Eli Lilly And Company | Modified glucagon-like peptide-1 analogs |
| EP1515746A2 (en) | 2002-06-11 | 2005-03-23 | Eisai Co. Ltd | Use of compounds having gip activity for the treatment of disorders associated with abnormal loss of cells and/or for the treatment of obesity |
| AU2003248676A1 (en) | 2002-06-15 | 2003-12-31 | Enteromed, Inc. | Treatment of non-alcoholic fatty liver disease |
| JP2006501820A (ja) | 2002-09-06 | 2006-01-19 | バイエル・フアーマシユーチカルズ・コーポレーシヨン | 修飾ｇｌｐ−１受容体アゴニストおよびそれらの薬理学的使用法 |
| US7192922B2 (en) * | 2002-11-19 | 2007-03-20 | Allegheny-Singer Research Institute | Method of treating left ventricular dysfunction |
| JP2006524039A (ja) | 2003-01-09 | 2006-10-26 | マクロジェニクス，インコーポレーテッド | 変異型Ｆｃ領域を含む抗体の同定および作製ならびにその利用法 |
| US20050059605A1 (en) | 2003-01-31 | 2005-03-17 | Krishna Peri | Chemically modified metabolites of regulatory peptides and methods of producing and using same |
| JP2007524579A (ja) * | 2003-02-19 | 2007-08-30 | ソシエテ・ドゥ・コンセイユ・ドゥ・ルシェルシュ・エ・ダプリカーション・シャンティフィック・エス・ア・エス | Ｇｌｐ−１の類似体 |
| WO2004078777A2 (en) | 2003-03-04 | 2004-09-16 | Biorexis Pharmaceutical Corporation | Dipeptidyl-peptidase protected proteins |
| EP1605897B1 (en) * | 2003-03-19 | 2012-07-25 | Eli Lilly And Company | Polyethelene glycol link glp-1 compounds |
| CA2521784C (en) * | 2003-04-08 | 2012-03-27 | Yeda Research And Development Co. Ltd. | Reversible pegylated drugs |
| TWI353991B (en) | 2003-05-06 | 2011-12-11 | Syntonix Pharmaceuticals Inc | Immunoglobulin chimeric monomer-dimer hybrids |
| AU2004240630B2 (en) | 2003-05-15 | 2010-10-07 | Trustees Of Tufts College | Stable analogs of peptide and polypeptide therapeutics |
| CA2527743A1 (en) | 2003-06-03 | 2004-12-09 | Novo Nordisk A/S | Stabilized pharmaceutical peptide compositions |
| EP1633391B1 (en) | 2003-06-03 | 2011-10-19 | Novo Nordisk A/S | Stabilized pharmaceutical peptide compositions |
| MXPA05013565A (es) * | 2003-06-12 | 2006-03-09 | Lilly Co Eli | Proteinas de fusion analogas al glp-1. |
| US20050124550A1 (en) * | 2003-06-18 | 2005-06-09 | Peri Krishna G. | Compounds that modulate the glucagon response and uses thereof |
| KR101241862B1 (ko) * | 2003-09-19 | 2013-03-13 | 노보 노르디스크 에이/에스 | 신규 ｇｌｐ-1 유도체 |
| US7364875B2 (en) * | 2003-10-30 | 2008-04-29 | Cresent Innovations, Inc. | Method for producing medical and commercial grade poly-gamma-glutamic acid of high molecular weight |
| MXPA06006745A (es) * | 2003-12-18 | 2006-08-18 | Novo Nordisk As | Compuestos glp-1 novedosos. |
| US20060286129A1 (en) * | 2003-12-19 | 2006-12-21 | Emisphere Technologies, Inc. | Oral GLP-1 formulations |
| US20080318837A1 (en) * | 2003-12-26 | 2008-12-25 | Nastech Pharmaceutical Company Inc. | Pharmaceutical Formation For Increased Epithelial Permeability of Glucose-Regulating Peptide |
| US8527752B2 (en) | 2004-06-16 | 2013-09-03 | Dormarke Assets Limited Liability | Graduated authentication in an identity management system |
| JP4666342B2 (ja) | 2004-07-26 | 2011-04-06 | ルネサスエレクトロニクス株式会社 | 半導体集積回路装置 |
| US20080305986A1 (en) * | 2004-08-16 | 2008-12-11 | Killian Waldemar Conde Fieboes | Multimers of Peptides |
| US7442682B2 (en) * | 2004-10-19 | 2008-10-28 | Nitto Denko Corporation | Transepithelial delivery of peptides with incretin hormone activities |
| BRPI0606992A2 (pt) * | 2005-02-11 | 2009-07-28 | Amylin Pharmaceuticals Inc | análogo e polipeptìdeos hìbridos de gip com propriedades selecionáveis |
| US8263545B2 (en) * | 2005-02-11 | 2012-09-11 | Amylin Pharmaceuticals, Inc. | GIP analog and hybrid polypeptides with selectable properties |
| WO2006097536A2 (en) * | 2005-03-18 | 2006-09-21 | Novo Nordisk A/S | Dimeric peptide agonists of the glp-1 receptor |
| WO2006121904A1 (en) | 2005-05-06 | 2006-11-16 | Bayer Pharmaceuticals Corporation | Glucose-dependent insulinotropic polypeptide (gip) receptor agonists and their pharmacological methods of use |
| PT1881850E (pt) | 2005-05-13 | 2010-11-26 | Lilly Co Eli | Compostos peguilados de glp-1 |
| RU2485135C2 (ru) | 2005-06-13 | 2013-06-20 | Импиэриэл Инноувейшнс Лимитид | Соединения оксинтомодулина (варианты), фармацевтическая композиция на их основе, способы лечения и профилактики ожирения и сопутствующих заболеваний (варианты) и лекарственное средство (варианты) |
| US7360772B2 (en) | 2005-07-20 | 2008-04-22 | Koch Hal D | Child transport air filtering system |
| EP2330124B1 (en) | 2005-08-11 | 2015-02-25 | Amylin Pharmaceuticals, LLC | Hybrid polypeptides with selectable properties |
| US20090286722A1 (en) | 2005-09-08 | 2009-11-19 | Utech Limited | Analogs of Gastric Inhibitory Polypeptide as a Treatment for Age Related Decreased Pancreatic Beta Cell Function |
| EP1943274A2 (en) | 2005-09-08 | 2008-07-16 | Uutech Limited | Treatment of diabetes related obesity |
| EP2570133B1 (en) * | 2005-11-07 | 2016-03-23 | Indiana University Research and Technology Corporation | Glucagon analogs exhibiting physiological solubility and stability |
| CN101389648B (zh) | 2006-02-22 | 2013-07-17 | 默沙东公司 | 肽胃泌酸调节素衍生物 |
| JP5312054B2 (ja) * | 2006-03-15 | 2013-10-09 | ノボ・ノルデイスク・エー／エス | アミリンとインスリンの混合物 |
| WO2007109354A2 (en) | 2006-03-21 | 2007-09-27 | Amylin Pharmaceuticals, Inc. | Peptide-peptidase inhibitor conjugates and methods of using same |
| ES2495741T3 (es) | 2006-04-20 | 2014-09-17 | Amgen, Inc | Compuestos de GLP-1 |
| WO2008022015A2 (en) | 2006-08-11 | 2008-02-21 | Trustees Of Tufts College | Retro-inverso incretin analogues, and methods of use thereof |
| AU2007284365A1 (en) * | 2006-08-17 | 2008-02-21 | Amylin Pharmaceuticals, Inc. | DPP-IV resistant GIP hybrid polypeptides with selectable properties |
| US20090318353A1 (en) | 2006-08-25 | 2009-12-24 | Novo Nordisk A/S | Acylated Exendin-4 Compounds |
| US20080053857A1 (en) | 2006-08-31 | 2008-03-06 | Paul Vincent Enriquez Albano | Package having two different views for increased awareness in display |
| CN106008699A (zh) * | 2006-09-08 | 2016-10-12 | Ambrx公司 | 经修饰的人类血浆多肽或Fc骨架和其用途 |
| US8617531B2 (en) | 2006-12-14 | 2013-12-31 | Bolder Biotechnology, Inc. | Methods of making proteins and peptides containing a single free cysteine |
| RU2477286C2 (ru) * | 2007-01-05 | 2013-03-10 | Индиана Юниверсити Рисерч Энд Текнолоджи Корпорейшн | АНАЛОГИ ГЛЮКАГОНА, ОБЛАДАЮЩИЕ ПОВЫШЕННОЙ РАСТВОРИМОСТЬЮ В БУФЕРАХ С ФИЗИОЛОГИЧЕСКИМ ЗНАЧЕНИЕМ pH |
| AU2008216265B2 (en) * | 2007-02-15 | 2014-04-03 | Indiana University Research And Technology Corporation | Glucagon/GLP-1 receptor co-agonists |
| JP5385266B2 (ja) * | 2007-06-15 | 2014-01-08 | ジーランド ファーマ アクティーゼルスカブ | グルカゴン類似体 |
| US7859468B2 (en) * | 2007-08-30 | 2010-12-28 | Research In Motion Limited | Mobile wireless communications device including a folded monopole multi-band antenna and related methods |
| EP2190872B1 (en) | 2007-09-05 | 2018-03-14 | Novo Nordisk A/S | Glucagon-like peptide-1 derivatives and their pharmaceutical use |
| WO2009030774A1 (en) | 2007-09-05 | 2009-03-12 | Novo Nordisk A/S | Truncated glp-1 derivatives and their therapeutical use |
| US20100256056A1 (en) | 2007-09-07 | 2010-10-07 | Zheng Xin Dong | Analogues of exendin-4 and exendin-3 |
| EP2036539A1 (en) | 2007-09-11 | 2009-03-18 | Novo Nordisk A/S | Stable formulations of amylin and its analogues |
| EP2036923A1 (en) | 2007-09-11 | 2009-03-18 | Novo Nordisk A/S | Improved derivates of amylin |
| US20100222251A1 (en) | 2007-09-11 | 2010-09-02 | Novo Nordisk A/S | Mixture comprising an amylin peptide and a protracted insulin |
| US8980830B2 (en) * | 2007-10-30 | 2015-03-17 | Indiana University Research And Technology Corporation | Peptide compounds exhibiting glucagon antagonist and GLP-1 agonist activity |
| WO2009058662A2 (en) | 2007-10-30 | 2009-05-07 | Indiana University Research And Technology Corporation | Glucagon antagonists |
| WO2009059278A1 (en) | 2007-11-02 | 2009-05-07 | Centocor, Inc. | Semi-synthetic glp-1 peptide-fc fusion constructs, methods and uses |
| AU2009210570B2 (en) * | 2008-01-30 | 2014-11-20 | Indiana University Research And Technology Corporation | Ester-based insulin prodrugs |
| MX2010008024A (es) | 2008-02-01 | 2010-12-21 | Ascendis Pharma As | Profarmaco que comprende un enlazador que se puede separar por si mismo. |
| DK2300035T3 (en) | 2008-06-17 | 2015-11-16 | Univ Indiana Res & Tech Corp | Mixed GIP-based agonists for the treatment of metabolic diseases and obesity |
| EP2300037B1 (en) * | 2008-06-17 | 2016-03-30 | Indiana University Research and Technology Corporation | Glucagon/glp-1 receptor co-agonists |
| WO2009155257A1 (en) * | 2008-06-17 | 2009-12-23 | Indiana University Research And Technology Corporation | Glucagon analogs exhibiting enhanced solubility and stability physiological ph buffers |
| CN102325539A (zh) | 2008-12-19 | 2012-01-18 | 印第安纳大学研究及科技有限公司 | 基于酰胺的胰高血糖素超家族肽前药 |
| CN102300580A (zh) | 2008-12-19 | 2011-12-28 | 印第安纳大学研究及科技有限公司 | 二肽连接的药剂 |
| WO2010096052A1 (en) | 2009-02-19 | 2010-08-26 | Merck Sharp & Dohme Corp. | Oxyntomodulin analogs |
| WO2010148089A1 (en) | 2009-06-16 | 2010-12-23 | Indiana University Research And Technology Corporation | Gip receptor-active glucagon compounds |
| US8703701B2 (en) | 2009-12-18 | 2014-04-22 | Indiana University Research And Technology Corporation | Glucagon/GLP-1 receptor co-agonists |
| AR079344A1 (es) | 2009-12-22 | 2012-01-18 | Lilly Co Eli | Analogo peptidico de oxintomodulina, composicion farmaceutica que lo comprende y uso para preparar un medicamento util para tratar diabetes no insulinodependiente y/u obesidad |
| AR079345A1 (es) | 2009-12-22 | 2012-01-18 | Lilly Co Eli | Analogo peptidico de oxintomodulina |
| EP2528618A4 (en) | 2010-01-27 | 2015-05-27 | Univ Indiana Res & Tech Corp | GLUCAGON ANTAGONISTE AND GIP AGONISTS CONJUGATES AND COMPOSITIONS FOR THE TREATMENT OF METABOLISM DISEASES AND ADIPOSITAS |
| AR080592A1 (es) | 2010-03-26 | 2012-04-18 | Lilly Co Eli | Peptido con actividad para el gip-r y glp-1-r, formulacion famaceutica que lo comprende, su uso para preparar un medicamento util para el tratamiento de diabetes mellitus y para inducir la perdida de peso |
| CA2797095A1 (en) | 2010-05-13 | 2011-11-17 | Indiana University Research And Technology Corporation | Glucagon superfamily peptides exhibiting nuclear hormone receptor activity |
| WO2011143208A1 (en) | 2010-05-13 | 2011-11-17 | Indiana University Research And Technology Corporation | Glucagon superfamily peptides exhibiting g protein-coupled receptor activity |
| RU2580317C2 (ru) | 2010-06-24 | 2016-04-10 | Индиана Юниверсити Рисерч Энд Текнолоджи Корпорейшн | Пептидные пролекарства, принадлежащие к суперсемейству амид-содержащих глюкагонов |
| WO2011163473A1 (en) | 2010-06-25 | 2011-12-29 | Indiana University Research And Technology Corporation | Glucagon analogs exhibiting enhanced solubility and stability in physiological ph buffers |
-
2009
- 2009-06-16 DK DK09800752.9T patent/DK2300035T3/en active
- 2009-06-16 HU HUE09800752A patent/HUE028072T2/en unknown
- 2009-06-16 MX MX2010013453A patent/MX2010013453A/es active IP Right Grant
- 2009-06-16 NZ NZ603445A patent/NZ603445A/en not_active IP Right Cessation
- 2009-06-16 TW TW098120096A patent/TWI474835B/zh not_active IP Right Cessation
- 2009-06-16 WO PCT/US2009/047447 patent/WO2010011439A2/en not_active Ceased
- 2009-06-16 BR BRPI0915282A patent/BRPI0915282A2/pt not_active IP Right Cessation
- 2009-06-16 KR KR1020107028260A patent/KR20110040760A/ko not_active Ceased
- 2009-06-16 CA CA2729296A patent/CA2729296A1/en not_active Abandoned
- 2009-06-16 PL PL09800752T patent/PL2300035T3/pl unknown
- 2009-06-16 US US12/999,285 patent/US9062124B2/en active Active
- 2009-06-16 ES ES15175377.9T patent/ES2650038T3/es active Active
- 2009-06-16 EA EA201001801A patent/EA020326B9/ru not_active IP Right Cessation
- 2009-06-16 CN CN201510309638.8A patent/CN104945500B/zh active Active
- 2009-06-16 AR ARP090102180A patent/AR072159A1/es not_active Application Discontinuation
- 2009-06-16 CN CN200980123349.1A patent/CN102105159B/zh active Active
- 2009-06-16 ES ES09800752.9T patent/ES2558842T3/es active Active
- 2009-06-16 SG SG2013045547A patent/SG192405A1/en unknown
- 2009-06-16 PE PE2009000874A patent/PE20100056A1/es not_active Application Discontinuation
- 2009-06-16 EP EP15175377.9A patent/EP2952202B1/en active Active
- 2009-06-16 EP EP09800752.9A patent/EP2300035B1/en active Active
- 2009-06-16 NZ NZ589848A patent/NZ589848A/xx not_active IP Right Cessation
- 2009-06-16 CL CL2009001425A patent/CL2009001425A1/es unknown
- 2009-06-16 AU AU2009274425A patent/AU2009274425B2/en not_active Ceased
- 2009-06-16 JP JP2011514735A patent/JP6108659B2/ja active Active
-
2010
- 2010-11-30 IL IL209666A patent/IL209666A/en not_active IP Right Cessation
- 2010-12-07 ZA ZA2010/08807A patent/ZA201008807B/en unknown
- 2010-12-15 MA MA33430A patent/MA32397B1/fr unknown
- 2010-12-16 EC EC2010010684A patent/ECSP10010684A/es unknown
- 2010-12-16 CO CO10158388A patent/CO6280539A2/es not_active Application Discontinuation
- 2010-12-16 CR CR11849A patent/CR11849A/es not_active Application Discontinuation
-
2015
- 2015-04-02 JP JP2015076371A patent/JP6174071B2/ja active Active
- 2015-05-18 US US14/714,728 patent/US20150322130A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2011524420A5 (https=) | ||
| JP2013518115A5 (https=) | ||
| JP4148994B2 (ja) | グルカゴン様ペプチド―２アナログ | |
| KR102440323B1 (ko) | 인크레틴 유사체 및 그의 용도 | |
| JP2011524418A5 (https=) | ||
| RU2014101697A (ru) | Коагонисты рецепторов глюкагона/glp-1 | |
| JP5890085B2 (ja) | 生理学的ｐＨの緩衝液中で向上した溶解度を示すグルカゴン類縁体 | |
| JP2014507402A5 (https=) | ||
| KR102092206B1 (ko) | 장기-작용성 glp-1/글루카곤 수용체 작용제 | |
| KR102092025B1 (ko) | 페길화된 옥신토모둘린 변이체 | |
| JP2012530145A5 (https=) | ||
| JP2010515686A5 (https=) | ||
| KR100905380B1 (ko) | 신경펩타이드-2 수용체(ｙ２ｒ) 작용물질 활성을 갖는펩타이드 | |
| CA2965560A1 (en) | Compositions and peptides having dual glp-1r and glp-2r agonist activity | |
| JP2011502159A5 (https=) | ||
| JP2014524908A5 (https=) | ||
| RU2012105355A (ru) | Производное аналога glp-1 или его фармацевтически приемлемые соли и их применение | |
| JP2012512903A5 (https=) | ||
| RU2012101274A (ru) | Соединения глюкагона, активные в отношении рецептора gip | |
| RU2014117678A (ru) | Пептиды глюкагонового суперсемейства, обладающие глюкокортикоидной рецепторной активностью | |
| CA2797089A1 (en) | Glucagon superfamily peptides exhibiting g protein-coupled receptor activity | |
| KR20150131213A (ko) | 인슐린-인크레틴 접합체들 | |
| JP2016512213A5 (https=) | ||
| JP2015528795A5 (https=) | ||
| JP2013533849A5 (https=) |